Anti-hla-g antibodies and methods of use thereof
AssigneeHoffmann-La Roche Inc.
InventorsStefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-HLA-G antibodies and methods of using the same.
Claims15
An isolated antibody that bind to human HLA-G;
- and that inhibits ILT2 binding to HLAG on JEG-3 cells (ATCC HTB36) and restores HLA-G specific suppressed TNF alpha release by monocytes co-cultured with JEG-3 cells.
An isolated antibody that bind to human HLA-G wherein the antibody comprises
- A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:3;
- and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4;
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6;
- or
- B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:11;
- and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12;
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14;
- or
- C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:19;
- and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20;
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22;
- or
- D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27;
- and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28;
- (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.
An isolated antibody that binds to human HLA-G, wherein the antibody
- a) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;
- or b) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.
The antibody according to any one of the preceding claims, wherein the antibody is of IgG1 isotype.
Isolated nucleic acid encoding the antibody according to any one of the preceding claims.
Dependencies are inferred from the claim text.